Patients with biomass exposure-related COPD (BE-COPD) is a prevalent disease in developing countries and requires a detailed study of its clinical and inflammatory characteristics, specifying interventions that may differ from tobacco exposure-related COPD (TE-COPD). The objective was to describe clinical characteristics, biomarkers of inflammation, T-helper cells, and microbiological agents during a COPD exacerbation in BE-COPD in comparison with TE-COPD. A prospective observational study in patients with moderate or severe exacerbation was recruited either in the emergency room or the COPD clinic. At enrollment, nasopharyngeal swabs and sputum were collected to identify viral and bacterial pathogens. Blood samples were also collected to measure inflammatory biomarkers and T-helper cells levels. Days of hospitalization and mechanical ventilation requirement was evaluated. Clinical characteristics, vaccination history, hospitalization, history of exacerbations, and microbiological pattern between BE-COPD and TE-COPD were similar. The Th2 profile was higher in BE-COPD than in TE-COPD (2.10 [range 1.30-3.30] vs. 1.40 [range 1.20-1.80], p = 0.001). The Th2/Th1 ratio was higher in BE-COPD than TE-COPD (1.22 [range 0.58-2.57 ] vs. 0.71 [range 0.40-1.15], p = 0.004). The need of mechanical ventilation (MV) was higher in TE-COPD than BE-COPD (13% vs. 31.1%, p = 0.01). Nonvaccination history and high CRP levels were significantly associated with hospitalization [OR 1.48 (CI 95% 1.30-4.61, p = 0.005) and OR 1.17 (CI 95% 1.10-1.24, p = 0.001), respectively]. Clinical characteristics, inflammatory markers, and microbiological isolates were similar in both groups but BE-COPD show a tendency to present higher inflammatory Th2 cells and low requirement MV compared with TE-COPD.
Background: COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV1) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City.Methods: A pilot, single-centre, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V and 34 COPD-C patients received UMEC/VI.Results: There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B (0.07 (95% CI 0.03–0.13), 0.06 (95% CI 0.03–0.12)) or COPD-C group (0.06 (95% CI 0.04–0.11), 0.08 (95% CI 0.05–0.13)), nor in the time of first exacerbation, nor FEV1and IC. All groups showed improvement in dyspnoea and HRQL, independently of medication used.Conclusions: Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnoea and HRQL.
Few treatment trials have been tested on COPD patients associated with biomass smoke exposure (COPD-B). Patients with COPD-B improve hyperinflation 24 hours after inhaling long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA), and after six months of treatment, improve symptoms, quality of life, and exacerbations. However, the usefulness of LAMA or LABA for an extended period for improving quality of life and symptoms has not yet been demonstrated in the COPD-B phenotype. The primary aim of this trial was to compare tiotropium (TIO) with indacaterol (IND) in improving the quality of life (QOL) measured by the Saint George's Respiratory Questionnaire (SGRQ) in COPD-B after six months of treatment. A randomized, open-label, parallel-group clinical trial designed at a third-level health institute in Mexico City. Seventy-three COPD-B women were randomly assigned to either 150 mcg of indacaterol or 18 mcg of tiotropium once daily for 24 weeks. 197 patients underwent the screening visit, of which 73 were randomized. There was no significant change in the three domains nor the total score of the SGRQ in either treatment group. For secondary outcomes, the TIO group showed a substantial change in the IC of 160 mL (p=0.016) after six month-treatment. For both treatment groups, a significant reduction in BDI/TDI score of 3 points was shown (p<0.001). Neither TIO nor IND improved quality of life, nor dyspnea evaluated by the mMRC scale, but TIO did improve inspiratory capacity, and TIO and IND improved dyspnea evaluated by BDI/TDI. NCT05506865.
Background: COPD ranks as the third leading global cause of mortality. Despite the widespread use of the BODE index and its variants for mortality prediction, their accuracy may be affected by factors like ethnicity, altitude and regional disparities. This study aimed to assess a new altitude-adapted prognostic index in COPD patients at moderate altitudes compared with the BODE and other mortality predictors.Methods: We evaluated the performance of BODE and other standard prognostic indexes in an exploratory cohort of COPD patients using Cox proportional hazards models. Additionally, we developed a new risk-weighted prognostics model. We assessed its performance utilising receiver operating characteristic curves and compared it with BODE index variants. The indices were validated in a second cohort. The mean follow-up period in both cohorts was 7 years.Results: In the exploratory cohort (n=416), COPD patients had a 77% 5-year survival rate. eBODE exhibited superior predictive capacity (HR 1.22, 95% CI 1.11–1.34, p<0.05). Prognostic models included oxygen saturation measured by pulse oximetry <90%, body mass index, 6-min walk test (6MWT) and current smoking as primary relevant risks (BOSEA-90), with the second model excluding 6MWT (BOSA-90). BOSEA-90 predicted a major risk per point (HR 1.41, 95% CI 1.31–1.51, p0.75) compared to other indices (AUC <0.70, p<0.001). The validation cohort (n=436) confirmed effectiveness in differentiating mild and very severe cases.Conclusions: The BODE prognostic index and its variants effectively predicted mortality, and the newly proposed BOSEA-90 and BOSA-90 indices demonstrated appropriate performance for a group of COPD patients at moderate altitude.
Introduction: having chronic obstructive pulmonary disease (COPD) and having COVID-19 results in greater aggression to the lungs and should be reflected in respiratory symptoms, quality of life and mental health. The aim of the study was to assess the impact of COVID-19 on dyspnea, quality of life and mental health in tobacco-associated COPD (COPD-TE) and biomass-associated COPD (COPD-BE). Methods: cross-sectional study in COPD-TE and COPD-BE with telephone survey during the pandemic, on sociodemographic data, quality of life (COPD Assessment Test, CAT), mental health (Hospital Anxiety and Depression Scale, HADS), comorbidities and COVID-19. We compared the quality of life and dyspnea of patients before the pandemic and during the pandemic, in patients who had COVID-19 and those who did not. Results: 18 patients with COPD-BE and 55 COPD-TE were evaluated. There was no difference between COPD-BE and COPD-TE in the frequency of COVID-19. COVID-19 did not affect dyspnea and lung function, but did affect quality of life assessed by CAT compared to the previous year and among those without COVID-19. Although there were no differences found in anxiety and depression between COVID-19 and non-COVID-19, a large percentage of patients had clinically significant levels of depression. Comorbidities were not a determinant for severity. Conclusions: COVID-19 affected both biomass and smoking COPD equally, with impairment on quality of life (CAT) in those with COVID-19.